{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:12:57Z","timestamp":1784041977572,"version":"3.55.0"},"posted":{"date-parts":[[2023,2,16]]},"group-title":"Cardiovascular Medicine","reference-count":50,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,2,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Diffuse myocardial fibrosis (DMF) quantified by extracellular volume (ECV) may represent a vulnerable phenotype and associate with life threatening ventricular arrhythmias more than focal myocardial fibrosis. This principle remains important because 1) risk stratification for implantable cardioverter defibrillators (ICD) remains challenging, and 2) DMF may respond to current or emerging medical therapies (reversible substrate).<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the association between quantified by ECV in myocardium without focal fibrosis by late gadolinium enhancement (LGE) with time from ICD implantation to 1) appropriate shock, or 2) shock or anti-tachycardia pacing.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Among patients referred for cardiovascular magnetic resonance (CMR) without congenital disease, hypertrophic cardiomyopathy, or amyloidosis who received ICDs (n=215), we used Cox regression to associate ECV with incident ICD therapy.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>After a median of 2.9 (IQR 1.5-4.2) years, 25 surviving patients experienced ICD shock and 44 experienced shock or anti-tachycardia pacing. ECV ranged from 20.2% to 39.4%. No patient with ECV&lt;25% experienced an ICD shock. ECV associated with both endpoints, e.g., hazard ratio 2.17 (95%CI 1.17-4.00) for every 5% increase in ECV, p=0.014 in a stepwise model for ICD shock adjusting for ICD indication, age, smoking, atrial fibrillation, and myocardial infarction, whereas focal fibrosis by LGE and global longitudinal strain (GLS) did not.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>DMF measured by ECV associates with ventricular arrhythmias requiring ICD therapy in a dose-response fashion, even adjusting for potential confounding variables, focal fibrosis by LGE, and GLS. ECV-based risk stratification and DMF representing a therapeutic target to prevent ventricular arrhythmia warrant further investigation.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Condensed Abstract<\/jats:title>\n                  <jats:p>Analogous to heart failure and mortality outcomes, diffuse myocardial fibrosis (DMF) quantified by extracellular volume (ECV) may represent a more vulnerable phenotype for life-threatening ventricular arrhythmia than focal myocardial fibrosis. In patients referred for cardiovascular magnetic resonance, we identified 215 subsequently receiving implantable cardioverter defibrillators (ICD). After a median of 2.9 (IQR 1.5-4.2) years, 25 patients experienced ICD shock and 44 experienced shock or anti-tachycardia pacing. ECV associated with ICD therapy in Cox regression models. Focal fibrosis variables or global longitudinal strain did not. ECV-based risk stratification and DMF representing a therapeutic target to prevent ventricular arrhythmia warrant further investigation.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2023.02.15.23285925","type":"posted-content","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T12:50:15Z","timestamp":1676551815000},"source":"Crossref","is-referenced-by-count":9,"title":["Diffuse myocardial fibrosis associates with incident ventricular arrhythmia in implantable cardioverter defibrillator recipients"],"prefix":"10.64898","author":[{"given":"Eric","family":"Olausson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathon","family":"Wertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaron","family":"Fridman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Bering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maren","family":"Maanja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Niklasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy C","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o L.","family":"Cavalcante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Cater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kellman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Bukhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Saba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Ugander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0356-4437","authenticated-orcid":false,"given":"Erik B.","family":"Schelbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2023021921451531000_2023.02.15.23285925v1.1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002613"},{"key":"2023021921451531000_2023.02.15.23285925v1.2","doi-asserted-by":"crossref","unstructured":"Treibel TA , Fridman Y , Bering P et al. Extracellular volume associates with outcomes more strongly than native or post-contrast myocardial T1. JACC Cardiovasc Imaging 2019;[Epub ahead of print]:.","DOI":"10.1016\/j.jcmg.2019.03.017"},{"key":"2023021921451531000_2023.02.15.23285925v1.3","doi-asserted-by":"crossref","first-page":"e009535","DOI":"10.1161\/CIRCIMAGING.119.009535","article-title":"Myocardial Extracellular Volume Fraction Adds Prognostic Information Beyond Myocardial Replacement Fibrosis","volume":"12","year":"2019","journal-title":"Circ Cardiovasc Imaging"},{"key":"2023021921451531000_2023.02.15.23285925v1.4","doi-asserted-by":"crossref","unstructured":"Fr\u00f6jdh F , Fridman Y , Bering P et al. Extracellular volume and global longitudinal strain both associate with outcomes but correlate minimally JACC Cardiovasc Imaging 2020;in press.","DOI":"10.1016\/j.jcmg.2020.04.026"},{"key":"2023021921451531000_2023.02.15.23285925v1.5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.089409"},{"key":"2023021921451531000_2023.02.15.23285925v1.6","first-page":"1320","article-title":"Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis","volume":"10","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"2023021921451531000_2023.02.15.23285925v1.7","doi-asserted-by":"crossref","unstructured":"Duca F , Zotter-Tufaro C , Kammerlander AA et al. Cardiac extracellular matrix is associated with adverse outcome in patients with chronic heart failure. Eur J Heart Fail 2016;Epub ahead of print.","DOI":"10.1002\/ejhf.680"},{"key":"2023021921451531000_2023.02.15.23285925v1.8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.116.005277"},{"key":"2023021921451531000_2023.02.15.23285925v1.9","first-page":"1","volume":"2","year":"2017","journal-title":"Temporal relation between myocardial fibrosis and heart failure with preserved ejection fraction: association with baseline disease severity and subsequent outcome JAMA Cardiol"},{"key":"2023021921451531000_2023.02.15.23285925v1.10","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht193"},{"key":"2023021921451531000_2023.02.15.23285925v1.11","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1007\/s00330-017-4817-9","article-title":"Contrast-enhanced T1 mapping-based extracellular volume fraction independently predicts clinical outcome in patients with non-ischemic dilated cardiomyopathy: a prospective cohort study","volume":"27","year":"2017","journal-title":"Eur Radiol"},{"key":"2023021921451531000_2023.02.15.23285925v1.12","doi-asserted-by":"crossref","unstructured":"Kanagala P , Cheng ASH , Singh A et al. Relationship Between Focal and Diffuse Fibrosis Assessed by CMR and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction. JACC Cardiovasc Imaging 2019.","DOI":"10.1016\/j.jcmg.2018.11.031"},{"key":"2023021921451531000_2023.02.15.23285925v1.13","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2006.095190"},{"key":"2023021921451531000_2023.02.15.23285925v1.14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.116.005619"},{"key":"2023021921451531000_2023.02.15.23285925v1.15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.1363"},{"key":"2023021921451531000_2023.02.15.23285925v1.16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.026910"},{"key":"2023021921451531000_2023.02.15.23285925v1.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.02.070"},{"key":"2023021921451531000_2023.02.15.23285925v1.18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.113.001768"},{"key":"2023021921451531000_2023.02.15.23285925v1.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.07.712"},{"key":"2023021921451531000_2023.02.15.23285925v1.20","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/eurheartj\/ehy437","article-title":"Reduction in mortality from implantable cardioverter-defibrillators in non-ischaemic cardiomyopathy patients is dependent on the presence of left ventricular scar","volume":"40","year":"2019","journal-title":"Eur Heart J"},{"key":"2023021921451531000_2023.02.15.23285925v1.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2016.09.017"},{"key":"2023021921451531000_2023.02.15.23285925v1.22","doi-asserted-by":"crossref","unstructured":"Pontone G , Guaricci AI , Andreini D et al. Prognostic Benefit of Cardiac Magnetic Resonance Over Transthoracic Echocardiography for the Assessment of Ischemic and Nonischemic Dilated Cardiomyopathy Patients Referred for the Evaluation of Primary Prevention Implantable Cardioverter-Defibrillator Therapy. Circ Cardiovasc Imaging 2016;9.","DOI":"10.1161\/CIRCIMAGING.115.004956"},{"key":"2023021921451531000_2023.02.15.23285925v1.23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.111.971549"},{"key":"2023021921451531000_2023.02.15.23285925v1.24","doi-asserted-by":"crossref","unstructured":"Voskoboinik A , Wong MCG , Elliott JK et al. Absence of late gadolinium enhancement on cardiac magnetic resonance imaging in ventricular fibrillation and nonischemic cardiomyopathy. Pacing Clin Electrophysiol 2018.","DOI":"10.1111\/pace.13426"},{"key":"2023021921451531000_2023.02.15.23285925v1.25","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.112.001511"},{"key":"2023021921451531000_2023.02.15.23285925v1.26","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.89.1.151"},{"key":"2023021921451531000_2023.02.15.23285925v1.27","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2828(08)80028-4"},{"key":"2023021921451531000_2023.02.15.23285925v1.28","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41591-021-01452-0","article-title":"Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial","volume":"27","year":"2021","journal-title":"Nat Med"},{"key":"2023021921451531000_2023.02.15.23285925v1.29","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.113.000438"},{"key":"2023021921451531000_2023.02.15.23285925v1.30","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.723262"},{"key":"2023021921451531000_2023.02.15.23285925v1.31","doi-asserted-by":"crossref","unstructured":"Schelbert EB , Butler J , Diez J. Why Clinicians Should Care About the Cardiac Interstitium. JACC Cardiovasc Imaging 2019.","DOI":"10.1016\/j.jcmg.2019.04.025"},{"key":"2023021921451531000_2023.02.15.23285925v1.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(01)01738-7"},{"key":"2023021921451531000_2023.02.15.23285925v1.33","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000416"},{"key":"2023021921451531000_2023.02.15.23285925v1.34","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.112.000022"},{"key":"2023021921451531000_2023.02.15.23285925v1.35","doi-asserted-by":"publisher","DOI":"10.1186\/1532-429X-13-16"},{"key":"2023021921451531000_2023.02.15.23285925v1.36","doi-asserted-by":"publisher","DOI":"10.1186\/1532-429X-15-92"},{"key":"2023021921451531000_2023.02.15.23285925v1.37","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.211.3.r99jn41698"},{"key":"2023021921451531000_2023.02.15.23285925v1.38","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002613"},{"key":"2023021921451531000_2023.02.15.23285925v1.39","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.mri.2019.05.029","article-title":"Myocardial native-T1 times are elevated as a function of hypertrophy, HbA1c, and heart rate in diabetic adults without diffuse fibrosis","volume":"61","year":"2019","journal-title":"Magn Reson Imaging"},{"key":"2023021921451531000_2023.02.15.23285925v1.40","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ijcard.2016.07.254","article-title":"Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis","volume":"222","year":"2016","journal-title":"Int J Cardiol"},{"key":"2023021921451531000_2023.02.15.23285925v1.41","doi-asserted-by":"crossref","unstructured":"Di Marco A , Brown PF , Bradley J et al. Extracellular volume fraction improves risk-stratification for ventricular arrhythmias and sudden death in non-ischaemic cardiomyopathy. Eur Heart J Cardiovasc Imaging 2022.","DOI":"10.1093\/ehjci\/jeac142"},{"key":"2023021921451531000_2023.02.15.23285925v1.42","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/jce.13226","article-title":"Substrate-dependent risk stratification for implantable cardioverter defibrillator therapies using cardiac magnetic resonance imaging: The importance of T1 mapping in nonischemic patients","volume":"28","year":"2017","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2023021921451531000_2023.02.15.23285925v1.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2014.12.020"},{"key":"2023021921451531000_2023.02.15.23285925v1.44","doi-asserted-by":"publisher","DOI":"10.1002\/mrm.24385"},{"key":"2023021921451531000_2023.02.15.23285925v1.45","doi-asserted-by":"publisher","DOI":"10.1002\/mrm.23153"},{"key":"2023021921451531000_2023.02.15.23285925v1.46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608029"},{"key":"2023021921451531000_2023.02.15.23285925v1.47","doi-asserted-by":"crossref","unstructured":"Selvanayagam JB , Hartshorne T , Billot L et al. Cardiovascular magnetic resonance-GUIDEd management of mild to moderate left ventricular systolic dysfunction (CMR GUIDE): Study protocol for a randomized controlled trial. Ann Noninvasive Electrocardiol 2017;22.","DOI":"10.1111\/anec.12420"},{"key":"2023021921451531000_2023.02.15.23285925v1.48","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(00)00729-3"},{"key":"2023021921451531000_2023.02.15.23285925v1.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2018.12.020"},{"key":"2023021921451531000_2023.02.15.23285925v1.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2018.07.015"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2023.02.15.23285925","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T19:27:13Z","timestamp":1768505233000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2023.02.15.23285925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,16]]},"references-count":50,"URL":"https:\/\/doi.org\/10.1101\/2023.02.15.23285925","relation":{},"subject":[],"published":{"date-parts":[[2023,2,16]]},"subtype":"preprint"}}